Sunil Healthcare Limited has announced its unaudited financial results for the third quarter and nine months ended December 31, 2025. The company's Board of Directors approved both standalone and consolidated financial results during their 266th Board Meeting held on February 06, 2026, which commenced at 4:17 p.m. and concluded at 5:55 p.m.

Q3 FY26 Financial Performance

The company's standalone financial performance for Q3 FY26 showed mixed results compared to the previous quarter. Revenue from operations declined to ₹2,183.73 lakhs from ₹2,351.76 lakhs in Q2 FY26, while net profit decreased to ₹44.30 lakhs from ₹78.90 lakhs in the previous quarter.

Nine Months Performance

For the nine months ended December 31, 2025, the standalone results showed revenue from operations of ₹6,799.69 lakhs with a net profit of ₹151.82 lakhs. Total expenses for the nine-month period amounted to ₹6,658.81 lakhs, resulting in a profit before tax of ₹220.60 lakhs.

Consolidated Results

The consolidated financial results include performance from the company's foreign subsidiaries - Sunil Healthcare Mexico Sa De CV and Sunil Healthcare North America LLC. For Q3 FY26, consolidated revenue from operations stood at ₹2,233.49 lakhs with a net profit of ₹58.52 lakhs.

Earnings Per Share and Other Details

The company reported basic and diluted earnings per share of ₹0.43 for Q3 FY26 on a standalone basis, compared to ₹0.77 in the previous quarter. For the nine months ended December 31, 2025, the earnings per share stood at ₹1.48.

Regulatory Compliance

The financial results were prepared in accordance with Indian Accounting Standard 34 "Interim Financial Reporting" and other accounting principles generally accepted in India. The results were reviewed by Singhi & Co., Chartered Accountants, who issued unqualified review reports for both standalone and consolidated financial statements. The company has complied with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Sunil Healthcare Limited has announced its unaudited financial results for the second quarter and first half of the fiscal year 2025-26, revealing a mixed performance across its standalone and consolidated operations.

Standalone Performance

For the quarter ended September 30, 2025, Sunil Healthcare's standalone revenue from operations stood at Rs. 235.76 lakhs, showing a slight improvement from Rs. 226.20 lakhs in the previous quarter. The company reported a standalone profit after tax of Rs. 7.90 lakhs for Q2 FY2026.

On a half-yearly basis, the standalone revenue reached Rs. 461.96 lakhs, up from Rs. 437.52 lakhs in the corresponding period of the previous year. The standalone profit after tax for the half-year period was Rs. 50.75 lakhs.

Consolidated Results

While the standalone figures showed positive trends, the consolidated results painted a different picture. The company reported a consolidated loss after tax of Rs. 5.64 lakhs for Q2 FY2026. For the half-year period, the consolidated operations recorded a loss of Rs. 18.47 lakhs.

Financial Highlights

All figures in Rs. lakhs

Board Meeting and Auditor's Review

The company's Board of Directors convened on November 4, 2025, to approve these financial results. The meeting, which started at 4:20 p.m. and concluded at 6:25 p.m., also saw the approval of limited review reports from the auditors.

Singhi & Co., Chartered Accountants, conducted an independent review of both the standalone and consolidated financial results. Their review reports, dated November 4, 2025, state that nothing has come to their attention that causes them to believe that the financial statements are not prepared in accordance with applicable accounting standards and SEBI regulations.

The divergence between standalone profit and consolidated loss suggests that Sunil Healthcare's subsidiaries may be facing challenges. The performance of the company's foreign subsidiaries, Sunil Healthcare Mexico Sa De CV and Sunil Healthcare North America LLC, could be contributing factors to the consolidated loss.

As Sunil Healthcare navigates through these mixed results, stakeholders will be keen to see how the company addresses the challenges in its consolidated operations while building on the positive momentum in its standalone performance.